Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Adapted from Center for Security and Emerging Technology using data from OECD and Global R&D Funding Forecast data; Chart: Andrew Witherspoon/Axios

The U.S. and China are the world's biggest spenders on research and development but still only make up about half of global investment in research, a recent report highlights.

The big picture: Competition between the two countries — measured by published papers, patents, educational degrees or the extent of investment — dominates discussions about global progress in science and technology.

  • That ignores significant R&D spending by a handful of countries that could be potential collaborators, argues Melissa Flagg of Georgetown University's Center for Security and Emerging Technology.

What's happening: Spending on R&D has grown around the world over the last 30 years and, at the same time, the U.S. share of global R&D fell.

  • During the Cold War, the U.S. accounted for an estimated 69% of global R&D; in 2018, it was 28%, according to the CSET report, which draws on data from OECD. China's spending is roughly the same global share.
  • "The R&D spending of the United States and just six like-minded nations with a true commitment to R&D funding represents more than 50 percent of global R&D investment," CSET's Melissa Flagg writes. She cites Japan and Germany as traditional heavy hitters but also countries like South Korea, which spent upwards of 3.8% of their GDP on R&D.

Why it matters: Flagg argues that reality is an opportunity for the U.S. to formally partner with countries and set standards and values around sharing data, transparency, reproducibility and research integrity. (The issue is of top concern because in international collaborations and open scientific exchange, some researchers or programs have not held the same values, jeopardizing U.S. research.)

  • Compared with formal efforts like the Human Genome Project or CERN, "the greater number of projects are 'bottom up' activities that are forged by researchers themselves, often with funding from their own governments, but where they seek to work with others because of the benefits of the science that results," says Ohio State University's Caroline Wagner.

Historically formal science and technology alliances came out of larger political ones and were taken for granted, says Flagg. "If you really believe technology is a foundation for critical aspects of leadership globally, economic security and military capability, then you can’t just have this be a sidebar for politicians."

  • And since the U.S., China and Europe are governed by different laws and values, she says, there needs to be a conversation rather than assuming European countries are onboard because China's tech is cheapest or because of tradition, in the case of the U.S. and its allies.

The bottom line: "No nation will enjoy complete global technological dominance," Flagg writes.

Go deeper: The stakes of a swift U.S.-China decoupling

Go deeper

Dave Lawler, author of World
Sep 24, 2020 - World

Global coronavirus vaccine initiative launches without U.S. or China

Data: Gavi, The Vaccine Alliance; Map: Naema Ahmed/Axios

A global initiative to ensure equitable distribution of coronavirus vaccines now includes most of the world — but not the U.S., China or Russia.

Why it matters: Assuming one or more vaccines ultimately gain approval, there will be a period of months or even years in which supply lags far behind global demand. The COVAX initiative is an attempt to ensure doses go where they're most needed, rather than simply to countries that can produce or buy them at scale.

Rep. Rice demands Cuomo resign after 3rd woman accuses him of misconduct

New York Gov. Andrew Cuomo during a February news conference in New York City. Photo: Seth Wenig/POOL/AFP via Getty Images

Rep. Kathleen Rice (D-N.Y.) on Monday evening called for New York Gov. Andrew Cuomo (D) to resign, after a third woman accused him of inappropriate behavior.

Driving the news: Anna Ruch, a former member of the Obama administration and the 2020 Biden campaign, told the New York Times Monday that Cuomo asked to kiss her at a New York City wedding reception in September 2019.

Scoop: Inside the GOP's plan to retake the House

House Minority Leader Kevin McCarthy. Photo: Elijah Nouvelage/Bloomberg via Getty Images

House Republicans will reclaim their majority in 2022 by offering candidates who are women, minorities or veterans, a memo obtained by Axios says.

Why it matters: The document, drafted by a super PAC blessed by House Minority Leader Kevin McCarthy, names top Democrats to target — Jared Golden of Maine, Matt Cartwright of Pennsylvania and Ron Kind of Wisconsin — and the type of Republican candidates to beat them.